Condition 1: Meniscus Tear. Condition 2: Rotator cuff tear. Condition 3: Bankart lesion. Condition 4: Anterior cruciate ligament tear. Tear of meniscus Injury of muscle(s) and tendon(s) of the rotator cuff of shoulder M24.4 Sprain and strain involving (anterior)(posterior) cruciate ligament of knee
Conditions
Interventions
Intervention 1: Intervention group1: They will receive Gabapentin capsule (300 mg)+ Celecoxib placebo 2 hour before surgery followed by the same amount of drug 12 hour post-operatively. Intervention 2
Treatment - Drugs
Placebo
Intervention group1: They will receive Gabapentin capsule (300 mg)+ Celecoxib placebo 2 hour before surgery followed by the same amount of drug 12 hour post-operatively.
Intervention group2: They will receive 2 Celecoxib capsules (200 mg)+ Gabapentin placebo 2 hour before surgery followed by the same amount of drug 12 hour post-operatively.
Intervention group3: They will receive 2 Celecoxib capsules (200 mg)+ Gabapentin capsule (300 mg) 2 hour before surgery followed by the same amount of drug 12 hour post-operatively.
Intervention group4: They will receive Celecoxib placebo+ Gabapentin placebo 2 hour before surgery followed by the same amount of drug 12 hour post-operatively.
Sponsors
Vice chancellor for research, Guilan University of Medical Science
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: age between 18 to 75 years old; Physical status according to ASA (grades:I,II, or III); VAS score more than 5; Operation time less than 1.5 hour; Oral and written consent form. Exclusion criteria: Any patients operated under local anesthesia; Hyper-sensitivity and/ or contra-indication to the drugs (Gabapentin or Celecoxib); History of coagulopathies or thromboembolic diseases; History of M.I, C.V.A, Epilepsy, Renal or hepatic dysfunction, Psychological disorders; Alcohol or drug abuse; usage of pain-killer drug up to 2 days before surgery; History of chronic pain and usually usage of pain-relief drugs.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total Pethedin usage. Timepoint: at 6 and 24 hour post surgery. Method of measurement: milligram.;Pain intensity. Timepoint: at 6 and 24 hour post surgery. Method of measurement: Visual analogue score. | — |
Secondary
| Measure | Time frame |
|---|---|
| Nausea/ vomiting. Timepoint: at 6 and 24 hour post surgery. Method of measurement: Classified as follow: 0 = not present, 1 = nausea, 2 = vomit and 3 = repeated vomit or need treatment.;Sedation score. Timepoint: at 6 and 24 hour post surgery. Method of measurement: 1 = completely awake, 2 = awake but drowsy, 3 = asleep but responsive to verbal commands, 4 = asleep but responsive to tactile stimulus and 5 = asleep and not responsive to any stimulus.;Dizziness. Timepoint: at 6 and 24 hour post surgery. Method of measurement: present/ not present. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMohsen Mardani Kivi MD.
Guilan University of Medical Science
Outcome results
None listed